Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Shahin Jamal"'
Autor:
Tatiana Nevskaya, Shahin Jamal, Ines Colmegna, Aurore Fifi-Mah, Nancy Maltez, Karam Al Jumaily, Annaliese Tisseverasinghe, Carrie Ye, Sabrina Hoa, Megan E. Himmel, Janet Roberts, Marie Hudson, Daniel Ennis, Janet E. Pope, Robert Rottapel, Christina Ly, Linda Laaouad, Alexandra Saltman
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2197-2207
Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD). Retrospective study of patients with PAD referred for rheumatologic evaluation prior to starting or du
Publikováno v:
Current Treatment Options in Rheumatology. 5:272-289
Immune checkpoint inhibitors (ICI) are now the cornerstone of treatment for metastatic melanoma and are increasingly used in many other advanced stage malignancies. Immune checkpoint inhibitors enhance the endogenous anti-tumor response by inhibiting
Autor:
Shahin Jamal, Edward C. Keystone, John Woolcott, Lara Fallon, Janet E. Pope, Douglass Chapman, Lisy Wang, Boulos Haraoui, Irina Lazariciu
Publikováno v:
Acr Open Rheumatology
ACR Open Rheumatology, Vol 1, Iss 2, Pp 73-82 (2019)
ACR Open Rheumatology, Vol 1, Iss 2, Pp 73-82 (2019)
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long‐term extension (LTE) studies up to 9.5 years. Methods Data
Autor:
Tarang Manchanda, Diana Fung, Shahin Jamal, Majed Khraishi, Vandana Ahluwalia, Boulos Haraoui
Publikováno v:
Rheumatology and Therapy
Rheumatology and Therapy, Vol 5, Iss 2, Pp 551-565 (2018)
Rheumatology and Therapy, Vol 5, Iss 2, Pp 551-565 (2018)
Introduction This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA). Methods This was a 12-month noninterventional, observa
Autor:
Timothy R D J Radstake, Marie Kostine, Jacques-Eric Gottenberg, Clifton O. Bingham, Thierry Schaeverbeke, Jan Leipe, Shahin Jamal, Andrew P. Cope, Axel Finckh, Olivier Lambotte, Yves Allenbach, James Larkin, K. Visser, Karolina Benesova, Cindy Rusthoven, Aurélien Marabelle, Ernest Choy, Leonard H. Calabrese, Hendrik Schulze-Koops, Marianne de Visser, John B. A. G. Haanen, Xavier Mariette, Lone Thomasen
Publikováno v:
Kostine, M, Finckh, A, Bingham, C O, Visser, K, Leipe, J, Schulze-Koops, H, Choy, E H, Benesova, K, Radstake, T R D J, Cope, A P, Lambotte, O, Gottenberg, J E, Allenbach, Y, Visser, M, Rusthoven, C, Thomasen, L, Jamal, S, Marabelle, A, Larkin, J, Haanen, J B A G, Calabrese, L H, Mariette, X & Schaeverbeke, T 2021, ' EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors ', Annals of the Rheumatic Diseases, vol. 80, no. 1, pp. 36-48 . https://doi.org/10.1136/annrheumdis-2020-217139
Annals of the Rheumatic Diseases, Vol. 80, No 1 (2021) pp. 36-48
Annals of the Rheumatic Diseases, Vol. 80, No 1 (2021) pp. 36-48
BackgroundRheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30f06a978d95a2dc367c911148c20c72
https://pure.au.dk/portal/da/publications/eular-points-to-consider-for-the-diagnosis-and-management-of-rheumatic-immunerelated-adverse-events-due-to-cancer-immunotherapy-with-checkpoint-inhibitors(39d74f68-fe47-45a0-9652-be867d636718).html
https://pure.au.dk/portal/da/publications/eular-points-to-consider-for-the-diagnosis-and-management-of-rheumatic-immunerelated-adverse-events-due-to-cancer-immunotherapy-with-checkpoint-inhibitors(39d74f68-fe47-45a0-9652-be867d636718).html
Autor:
Sabrina Hoa, Alexandra Saltman, Shahin Jamal, Carrie Ye, Janet E. Pope, Annaliese Tisseverasinghe, Megan E. Himmel, Aurore Fifi-Mah, Janet Roberts, Robert Rottapel, Marie Hudson, Daniel Ennis, Nancy Maltez
Publikováno v:
Autoimmunity reviews. 19(8)
Objective Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related adverse events (irAE). Here we describe the clinical presentation and management of
Publikováno v:
The Journal of rheumatology. 47(2)
Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune system to fight cancer cells. Their use is often limited by the development of autoimmune toxicities, which can affect multiple organ system
Publikováno v:
Abstracts Accepted for Publication.
Background Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. However, enhanced immune activation from ICI has been associated with immune-related adverse events (irAE), including autoimmune rheumatologic diseases such as
Autor:
Kam Shojania, Daniel J. Clauw, Shahin Jamal, Zach Walsh, Yoram Shir, Tara Landry, Peter A. Ste-Marie, Jacob Karsh, Mary Ann Fitzcharles, Jason J. McDougall, Winfried Häuser, Sharon LeClercq
Publikováno v:
Arthritis Care & Research. 68:681-688
Objective To assess the efficacy, tolerability, and safety of cannabinoids (phyto- and syntheto-) in the management of rheumatic diseases. Methods Multiple databases, including Medline, Embase, and CENTRAL, were searched. Randomized controlled trials
Autor:
T. Schaeverbeke, Olivier Lambotte, Hendrik Schulze-Koops, X. Mariette, Aurélien Marabelle, K. Visser, Axel Finckh, Karolina Benesova, Shahin Jamal, E.H. Choy, Clifton O. Bingham, Timothy R D J Radstake, J.-E. Gottenberg, L. Calabrese, M. Kostine, J.M.G. Larkin, J. Leipe, Y. Allenbach, Andrew P. Cope, J.B.A.G. Haanen
Publikováno v:
Annals of Oncology. 30:v528
Background Rheumatic immune-related adverse events (irAEs) are increasingly recognized musculoskeletal manifestations in cancer patients receiving immune checkpoint targeted immunotherapy. Since they represent a spectrum of new clinical entities and